药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Ebastine
The risk or severity of QTc prolongation can be increased when Ebastine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Difloxacin
The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Sarafloxacin
The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Phosmet
The risk or severity of QTc prolongation can be increased when Phosmet is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Orbifloxacin
The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Fenthion
The risk or severity of QTc prolongation can be increased when Fenthion is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Famphur
The risk or severity of QTc prolongation can be increased when Famphur is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Dichlorvos
The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Coumaphos
The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Acrivastine
The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Lacidipine
The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Efonidipine
The risk or severity of QTc prolongation can be increased when Efonidipine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Aranidipine
The risk or severity of QTc prolongation can be increased when Aranidipine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Pinaverium
The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Trimebutine
The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Vilanterol
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Olodaterol
The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Flumequine
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Chlorcyclizine
The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Eribulin
The risk or severity of QTc prolongation can be increased when Eribulin is combined with Berotralstat.